Cargando…
Zanamivir for the prevention of influenza in adults and children age 5 years and older
On a yearly basis there are 3–5 million severe cases and 250,000–500,000 deaths worldwide attributed to influenza. Four antiviral medications are currently available on the market; however, resistance has resulted in the armamentarium being shrunk to two remaining active treatment options for influe...
Autores principales: | Eiland, Lea S, Eiland, Edward H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386359/ https://www.ncbi.nlm.nih.gov/pubmed/18488077 |
Ejemplares similares
-
The Basics of Penicillin Allergy: What A Clinician Should Know
por: Lteif, Louis, et al.
Publicado: (2019) -
Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
por: Gresham, Jessica, et al.
Publicado: (2010) -
Intravenous zanamivir for influenza myocarditis and enteral malabsorption
por: Jahns, Fritz-Patrick, et al.
Publicado: (2018) -
Retrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-Resistant Staphylococcus aureus Complicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid
por: Wright, Bradley M., et al.
Publicado: (2011) -
Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments
por: Heneghan, Carl J, et al.
Publicado: (2014)